Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Seer, Inc.NASDAQ: SEER

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $2.79M fell 33.6% year over year, behind the -0.9% change in trailing-twelve-month revenue. Sequentially, it fell 31.4% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $15.12M (-6.2%) for the fiscal year ending Dec 2026, a slowdown from the +15.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.79M-31.4% QoQ
Last fiscal yearDec 2025
$16.12M+15.6% YoY
LTMMar 2026
$15.04M-0.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.6%-12.4%+21.2 pp
1 year+15.6%-6.2%-21.7 pp
3-year CAGR+3.2%+13.7%+10.6 pp
5-year CAGR+24.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
16.12M USD
Year-over-year change
+15.6%
4-year CAGR
+26.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -0.9% is the 4th highest of 10, against a peer median of -46.2%.
  • Over three fiscal years its annual growth of +3.2% compares with a peer median of +10.1%.
SEER Competitors
Revenue for SEER and competitors
Company Period LTM YoY 3-year CAGR
NRIXNurix Therapeutics, Inc.LTM Aug 2026$701.94M USD+738.8%+29.5%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$104.99M USD+134.8%-5.8%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$42.95M USD-73.1%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.86M USD-12.4%+5.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$28.22M USD+20.1%+17.1%
SEERSeer, Inc.LTM Mar 2026$15.04M USD-0.9%+3.2%
QSIQuantum-Si incorporatedLTM Mar 2026$1.85M USD-46.2%—
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
MNOVMediciNova, Inc.LTM Mar 2026$596.64K USD——
LYELLyell Immunopharma, Inc.LTM Mar 2026$31K USD-52.3%-92.5%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR——
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$0 USD——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 USD——
SANASana Biotechnology, Inc.LTM Mar 2026$0 USD——
PEPGPepGen Inc.LTM Mar 2026$0 USD——
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD——
MOLNMolecular Partners AGLTM Mar 2026CHF 0 CHF-100.0%—
NKTXNkarta, Inc.LTM Mar 2026$0 USD——
Peer median (excluding SEER) —-46.2%+10.1%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.